Literature DB >> 11805217

Immunopharmacological potential of selective phosphodiesterase inhibition. I. Differential regulation of lipopolysaccharide-mediated proinflammatory cytokine (interleukin-6 and tumor necrosis factor-alpha) biosynthesis in alveolar epithelial cells.

John J Haddad1, Stephen C Land, William O Tarnow-Mordi, Marek Zembala, Danuta Kowalczyk, Ryszard Lauterbach.   

Abstract

In an attempt to elaborate in vitro on a therapeutic strategy that counteracts an inflammatory signal, we previously reported a novel immunopharmacological potential of glutathione, an antioxidant thiol, in regulating inflammatory cytokines. In the present study, we investigated the hypothesis that selective regulation of phosphodiesterases (PDEs), a family of enzymes that controls intracellular cAMP/cGMP degradation, differentially regulates proinflammatory cytokines. Selective PDE1 inhibition (8-methoxymethyl-3-isobutyl-1-methylxanthine) blockaded lipopolysaccharide-endotoxin (LPS)-mediated biosynthesis of interleukin (IL)-6, but this pathway had no inhibitory effect on tumor necrosis factor-alpha (TNF-alpha). Furthermore, inhibition of PDE3 (amrinone) abolished the effect of LPS on IL-6, but attenuated TNF-alpha production. Reversible competitive inhibition of PDE4 (rolipram) exhibited a potent inhibitory effect on IL-6 and a dual, biphasic (excitatory/inhibitory) effect on TNF-alpha secretion. Blockading PDE5 (4-[[3',4'-(methylenedioxy)benzyl] amino]-6-methoxyquinazoline) showed a high potency in reducing IL-6 production, but in a manner similar to the inhibition of PDE4, exhibited a biphasic effect on TNF-alpha biosynthesis. Simultaneous inhibition of PDE5, 6, and 9 (zaprinast), purported to specifically elevate intracellular cGMP, reduced, in a dose-independent manner, IL-6 and TNF-alpha biosynthesis. Finally, nonselective inhibition of PDE by pentoxifylline suppressed LPS-mediated secretion of IL-6 and TNF-alpha. The involvement of specific PDE isoenzymes in differentially regulating LPS-mediated inflammatory cytokine biosynthesis indicates a novel approach to unravel the potential therapeutic targets that these isozymes constitute during the progression of inflammation within the respiratory epithelium.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11805217     DOI: 10.1124/jpet.300.2.559

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  25 in total

Review 1.  PDE4 inhibitors: current status.

Authors:  D Spina
Journal:  Br J Pharmacol       Date:  2008-07-28       Impact factor: 8.739

2.  Protein phosphatases and chromatin modifying complexes in the inflammatory cascade in acute pancreatitis.

Authors:  Javier Escobar; Javier Pereda; Alessandro Arduini; Juan Sandoval; Luis Sabater; Luis Aparisi; Gerardo López-Rodas; Juan Sastre
Journal:  World J Gastrointest Pharmacol Ther       Date:  2010-06-06

3.  A pathophysiological role of PDE3 in allergic airway inflammation.

Authors:  Jan Beute; Melanie Lukkes; Ewout P Koekoek; Hedwika Nastiti; Keerthana Ganesh; Marjolein Jw de Bruijn; Steve Hockman; Menno van Nimwegen; Gert-Jan Braunstahl; Louis Boon; Bart N Lambrecht; Vince C Manganiello; Rudi W Hendriks; Alex KleinJan
Journal:  JCI Insight       Date:  2018-01-25

4.  Pentoxifylline alleviates vascular impairment in insulin resistance via TNF-α inhibition.

Authors:  Hany M El-Bassossy; Mohamed A El-Moselhy; Mona F Mahmoud
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2011-07-29       Impact factor: 3.000

5.  Steroid-sparing effects of pentoxifylline in pulmonary sarcoidosis.

Authors:  M K Park; H Babaali; L I Gilbert-McClain; M Stylianou; J Joo; J Moss; V C Manganiello
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2009-07       Impact factor: 0.670

6.  Tadalafil analgesia in experimental arthritis involves suppression of intra-articular TNF release.

Authors:  F A C Rocha; F S Silva; A C R M Leite; A K R M Leite; V C C Girão; R R Castro; F Q Cunha
Journal:  Br J Pharmacol       Date:  2011-09       Impact factor: 8.739

7.  Effect of cilomilast (Ariflo) on TNF-alpha, IL-8, and GM-CSF release by airway cells of patients with COPD.

Authors:  M Profita; G Chiappara; F Mirabella; R Di Giorgi; L Chimenti; G Costanzo; L Riccobono; V Bellia; J Bousquet; A M Vignola
Journal:  Thorax       Date:  2003-07       Impact factor: 9.139

Review 8.  Phosphodiesterase-4 inhibitors in the treatment of inflammatory lung disease.

Authors:  Domenico Spina
Journal:  Drugs       Date:  2003       Impact factor: 9.546

Review 9.  Dual PDE3/4 inhibitors as therapeutic agents for chronic obstructive pulmonary disease.

Authors:  Katharine H Banner; Neil J Press
Journal:  Br J Pharmacol       Date:  2009-06-05       Impact factor: 8.739

10.  Inhaled milrinone attenuates experimental acute lung injury.

Authors:  Moritz Bueltmann; Xiang Kong; Michael Mertens; Ning Yin; Jun Yin; Zhongmin Liu; Andreas Koster; Hermann Kuppe; Wolfgang M Kuebler
Journal:  Intensive Care Med       Date:  2008-10-30       Impact factor: 17.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.